Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06301412
Other study ID # COTTIS-2_Version4.0-13Nov23
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date March 18, 2024
Est. completion date June 18, 2026

Study information

Verified date March 2024
Source University of Freiburg
Contact Juergen Bardutzky, Prof.
Phone +49-15237729739
Email juergen.bardutzky@uniklinik-freiburg.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test the combination of hypothermia and endovascular treatment in acute stroke patients with large vessel occlusion. The main question it aims to answer is: does an additional cooling to 35°C result in a benefit on clinical outcome ? Participants receive immediate cooling using a noninvasive transnasal cooling technique (RhonoChill) and are maintained at 35°C for 6 hours after reopening of the vessel using surface cooling, and then slowly rewarmed. Researchers will compare the intervention group (hypothermia and endovascular treatment and best medical treatment including iv thrombolysis) and control group (only endovascular treatment and best medical treatment including iv thrombolysis) to see if additional hypothermia leads to a better outcome after 3 months without relevant complications.


Description:

Despite the well-established benefit of endovascular treatment (EVT) for acute ischemic stroke due to large vessel occlusion (LVO), more than half of patients treated with EVT remain functionally dependent despite high reperfusion rates. Thus, new strategies such as additional neuroprotection using hypothermia need to be explored, first to bridge time to reperfusion and second, to attenuate reperfusion injury. Although therapeutic hypothermia has consistently demonstrated robust neuroprotection in animal ischemic-reperfusion models, randomized trials in acute stroke patients have failed to demonstrate the efficacy of induced hypothermia. The reasons for this treatment failure are diverse and include treatment delay, the unfeasibility of inducing and maintaining hypothermia due to intolerance and shivering in awake patients, the missing recanalization in a large proportion of patients, the heterogeneity of patients included, and too deep (32-34°C) hypothermia associated with an increase in side effects. In the pilot study COTTIS-1, we could demonstrate the feasibility and safety of immediately induced intraischemic hypothermia to 35°C with non-invasive transnasal cooling by RhinoChill® (BrainCool) followed by surface cooling for 6h after recanalization in sedated and intubated patients with LVO undergoing EVT. By combining this cooling technique with thrombectomy we have tried to address the above mentioned reasons for hypothermia failure. In COTTIS-1, the target temperature of 35°C was reached within 30 min, corresponding to a cooling rate of 2.6°C/h. All patients reached the target temperature, and 86% of the patients had reached ≤35°C at recanalization by thrombectomy. 68% of patients had a good outcome (independency) after 3 months. There were only asymptomatic side effects during hypothermia. As a consequence, the present COTTIS-2 study is planned to evaluate the efficiency of this cooling protocol in a multicentric, randomized, controlled, end-point-blinded study in Germany.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 400
Est. completion date June 18, 2026
Est. primary completion date March 18, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pre-stroke modified Rankin Scale (mRS) 0-2 [7-point scale rating from 0 (no symptoms) to 6 (dead)] - Acute ischemic stroke with NIHSS >5 - Intracranial occlusion of the M1 or M2 segment of the middle cerebral artery (MCA) or internal carotid artery (ICA) or tandem occlusion on CT-angiography or MR-angiography with indication for endovascular treatment: - Time window 0-24h: 1. Last seen normal to groin puncture < 6h: native CT or MRI-DWI with ASPECTS >5 2. Last seen normal to groin puncture 6-24h or unknown time window: significant mismatch imaging according to the eligibility criteria of the DEFUSE-3 trial - Infarct core <70ml (DWI oder CBF<30%) - Penumbra > 15ml (Tmax >6sec) - Ratio penumbra/core >1.8 - with or without iv thrombolysis with rtPA Exclusion Criteria: - Patients with an intranasal obstruction that prevents complete insertion of the nasal cannula should not be treated with the RhinoChill system. - Known severe hemorrhagic diathesis (International Normalized Ratio (INR) >3.0, partial thromboplastin time (PTT) > 70s, platelet count < 50.000/µl) - Brain trauma or neurovascular surgery/intervention <3 months - Severe infection - Pregnant women or women of childbearing potential (women of childbearing potential with negative pregnancy test may be included) - Known cerebral vasculitis - Proof of bleeding in cerebral CT or MRI (cerebral microbleeds in MRI [hypertensive or in the context of cerebral amyloid angiopathy] is permitted). - Known life expectancy < 6 months

Study Design


Intervention

Device:
hypothermia
hypothermia is started after intubation for endovascular treatment and induced by transnasal cooling (RhinoChill) to a target temperature of 35°C and hypothermia is then maintained at 35°C for 6 hours after recanalisation by surface cooling followed by slow rewarming by 0.2°C per hour to 36.5°C

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
University of Freiburg Center for Medical data science, University of Vienna, Austria, E+E CRO consulting, Vienna, Austria, European Union

Outcome

Type Measure Description Time frame Safety issue
Other Occurrence of intracerebral haemorrhage (ICH) Any ICH (subarachnoid, intraparenchymal, intraventricular) on the CT after 24 hours
Symptomatic ICH (defined according to SITS-MOST criteria):
Hematoma >30% of initial infarction volume associated with a clinical deterioration in NIHSS score of at least 4 points within 24 hours after thrombectomy
24 hours
Other Complications associated with hypothermia Nosebleed and pailing of the nose
Periorbital emphysema
Pneumocephalus (in 24-hour control CT)
Blood pressure, heart rate, oxygen saturation SO2
Episodes with severe hypotension with systolic blood pressure <110mmHg
Incidence of pneumonia (defined as: any new pulmonary infiltrate on radiographic imaging occurring <48hrs after admission combined with at least one of the subsequent findings: fever >38°C, leukopenia/leucocytosis, purulent secretions with positive cultures)
Disturbances in electrolytes, renal function, coagulation (potassium, sodium, chloride, creatinine, INR, pTT, thrombocytes measured on admission before hypothermia and at 24 hours)
24hours
Primary functional outcome The presence of patients with good neurological outcome after 3 months as defined by modified Rankin Scale (mRS; on which scores range from 0 to 6, with 0 means no symptoms and 6 means death) of 0-2 3 months
Secondary infarction volume Infarction volume assessed in the standard CT 24 hours after thrombectomy 24 hours
Secondary increase in infarction increase of the infarct core based on imaging at the time of admission (DWI-MRI or CBF<30% of contralateral side at CT-Perfusion) and CT after 24 hours 24 hours
Secondary recanalization result Recanalization result (by mTICI score: successful recanalization mTICI 2b-3) after thrombectomy (based on angiography during/after thrombectomy) and 24 hours after thrombectomy (based on ultrasound of the cerebral vessels) after thrombectomy and 24 hours
Secondary neurological improvement Change of at least 8 points on the National Institutes of Health Stroke Scale (NIHSS; on which scores range from 0 to 42, with higher scores indicating a greater deficit) at 48 hours after thrombectomy 48 hours
Secondary outcome at discharge modified Rankin Score (mRS; on which scores range from 0 to 6, with 0 means no symptoms and 6 means death) upon discharge/transfer in rehabilitation up to 3 months
Secondary shift in functional outcome ordinal shift across the range of modified Rankin Score (mRS; on which scores range from 0 to 6, with 0 means no symptoms and 6 means death) 3 months
Secondary very good clinical outcome Presence of patients with very good clinical outcome after 3 months (mRS 0-1) 3 months
Secondary mortality Mortality during acute hospitalisation and after 3 months 3 months
Secondary Length of ventilation Length of mechanical ventilation 3 months
Secondary Length of stay Length of ICU stay and hospital stay 3 months
Secondary body temperature Temperature at admission, at recanalization, and first 6 hours after recanalization, and at 24 hours 24 hours
Secondary time to groin puncture Time from arrival until groin puncture baseline, pre-intervention
Secondary time to recanalization Time from arrival until recanalization periprocedurally
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2